Position in HLN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$2,064,607
+$107,172 QoQ
Shares Held
221,287
+13.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#106
of 640 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 18%
Shared 0%
None 82%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Focus Partners Wealth holds $57,760,663 across 23 Drug Manufacturers - Specialty & Generic names. HLN ranks #7 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
77,994 | $13,145,108 | |
| 2 | ZTS |
Zoetis Inc.
|
180,366 | $12,961,100 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
679,950 | $10,899,598 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
67,843 | $7,526,502 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
6,078 | $3,293,242 | |
| 6 | ALKS |
Alkermes plc.
|
41,596 | $2,179,630 | |
| 7 | HLN |
Haleon plc
This page
|
221,287 | $2,064,607 | |
| 8 | TEVA |
Teva Pharmaceutical Industries Ltd
|
35,560 | $1,204,772 |
All Filings in HLN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,064,607 | 221,287 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $1,957,435 | 195,548 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,728,516 | 170,971 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,386,448 | 154,565 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $854,685 | 82,419 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $752,260 | 73,106 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $648,033 | 67,928 | Shares | Sole | 2025-05-20 | |
| 2024-09-30 | $309,750 | 29,277 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $237,242 | 28,722 | Shares | Sole | 2024-08-15 | |
| No filing history on record for this holder in this stock. | ||||||